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Abstract
The identification of genes undergoing genetic or epi-
genetic alterations and contributing to the develop-
ment of cancer is critical to our understanding of the
molecular mechanisms of carcinogenesis. A new ap-
proach in identifying alterations of genes that might
be relevant to the process of tumor development was
used in this study by examining the gene expression
profile in human lung cancer cells exposed to 5-aza-2V-
deoxycytidine (5-aza-dC). A cDNA array analysis was
carried out on 5-aza-dC–treated and untreated non
small cell lung cancer (NSCLC) cell line NCI-H522.
Sixteen and 14 genes were upregulated and down-
regulated, respectively, by 5-aza-dC treatment. Among
them, downregulation of tyrosine protein kinase ABL2
(ABL2 ) gene and upregulation of hint/protein kinase
C inhibitor 1 (Hint/PKCI-1), DVL1, TIMP-1, and TRP-1
genes were found in expanded observations in two
or three of five 5-aza-dC–treated NSCLC cell lines.
Among these genes, we found that cDNA transfer of
Hint/PKCI-1 resulted in a significant in vitro growth
inhibition in two cell lines exhibiting 5-aza-dC–induced
upregulation of Hint/PKCI-1 and significantly reduced
in vivo tumorigenicity of one NSCLC cell line. Hint/
PKCI-1, which is the only other characterized human
histidine triad (HIT) nucleotide-binding protein in addi-
tion to tumor-suppressor gene FHIT, might be involved
in lung carcinogenesis.
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Introduction
Lung cancer, the majority of which are non small cell lung
carcinoma (NSCLC), is the leading cause of cancer death in
men and women in the United States [1]. Although most
lung cancers are related to tobacco use, it is also ranked
second only to bladder cancer in the proportion cases
thought to be due to occupational exposures [2]. Increasing
evidence demonstrates that the accumulation of epigenetic
damage induced by the respiratory epithelium to cigarette
smoke and/or occupational carcinogens is one of the major
mechanisms responsible for the development of lung cancer.
Epigenetic damage, consisting mainly of promoter hyperme-
thylation, disrupts or silences the expression of tumor-suppres-
sor genes, leading to uncontrolled cell proliferation. There are
an increasing number of candidate tumor-suppressor genes
that are inactivated by promoter hypermethylation in various
types of cancer. In human cancer, promoter hypermethylation
appears to be involved at least as frequently as point mutations
in the disruption of tumor-suppressor genes [3]. Promoter
hypermethylation in tumor-suppressor genes, such as p16,
death-associated protein kinase (DAPK), FHIT, and Ras effec-
tor homologue (RASSF1A), is thought to be an early event in
cigarette smoking–related respiratory carcinogenesis [4–6].
One major challenge in lung cancer investigations is the
identification of genes that undergo genetic or epigenetic
damage during neoplastic development. The basic strategy
employed for identifying new candidate genes was the com-
parison of gene expression between cancer cells and the cor-
responding noncancerous cells, or between parental tumor
cells and anti– tumor agent–treated tumor cells. The compar-
ison of gene expression between 5-aza-2V-deoxycytidine
(5-aza-dC)–treated and parental tumor cell lines is a feasible
approach for the identification of differentially expressed
cancer-related genes [7,8].
5-Aza-dC is the most commonly used DNA demethylation
agent and can induce tumor cell differentiation, cell cycle
arrest, and apoptosis [9–13]. It is believed that the multiple
effects of 5-aza-dC on tumor cells derive from its ability to
inhibit DNA methyltransferase during DNA synthesis, lead-
ing to DNA demethylation and subsequent activation of the
expression of transcriptionally silenced genes [14–16]. The
majority of genes activated by 5-aza-dC, such as Rb, p16,
E-cadherin, APC, VHL, retinoic acid receptor b, BRCA1, and
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DLC-1, are tumor-suppressor genes in different types of
cancer cells [17–25]. It is known that tumor-suppressor
genes can negatively regulate the function of oncogenes
or genes promoting tumor cell growth through different
signal transduction pathways. Therefore, it is presumed
that 5-aza-dC exerts its antitumor function by directly upre-
gulating tumor-suppressor genes through DNA demethyla-
tion, and by indirectly downregulating oncogenes through
signal transduction pathways. Thus, changes in gene ex-
pression, especially the upregulation of tumor-suppressor
genes and the downregulation of oncogenes, would be
expected in each tumor cell line, which is responsive to
5-aza-dC in cell growth inhibition, cell cycle arrest, or
apoptosis, during the transition of DNA methylation status
rendered by 5-aza-dC treatment. It can also be understood
that the transition of DNA methylation status can provide
an opportunity to identify tumor-related genes, either
tumor-suppressor gene(s) or oncogene(s).
In this study, we employed a cDNA array to analyze the
changes in gene expression in an in vitro 5-aza-dC–treated
human lung adenocarcinoma cell line. Treatment of this cell
line with 5-aza-dC resulted in growth inhibition, cell cycle
arrest, apoptosis, and changes in mRNA expression of
several genes. Among them, the hint/protein kinase C inhib-
itor 1 (Hint/PKCI-1) gene was upregulated by 5-aza-dC and
inhibited lung tumor cells growth.
Materials and Methods
Reagents and Cell Culture
5-Aza-dC was purchased from Sigma (St. Louis, MO).
Atlas Human Cancer 1.2 Array, carrying cDNA fragments of
a total of 1176 individual genes, was purchased from Clon-
tech (Palo Alto, CA). In Situ Cell Death Detection (TDT-
mediated dUTP biotin nick end labeling [TUNEL] assay) Kit
was purchased from Roche Molecular Biochemicals (Indian-
apolis, IN). Human NSCLC cell lines A539, NCI-H23, NCI-
H358, NCI-H522, and NCI-H520 were purchased from
ATCC (Rockville, MD) and cultured in RPMI 1640 medium
(Gibco BRL, Gibco, Carlsbad, CA) containing 10% of fetal
bovine serum and 100 U of penicillin and streptomycin.
Cell Proliferation Assay, TUNEL Assay (In Vitro Cell Death
Assay), and Cell Cycle Analysis for 5-Aza-dC–Treated NCI-
H522 Cells
In cell proliferation assays, 1  105 cells were seeded in
each T-25 culture flask in triplicate. Cells were either treated
or untreated with 1 mM 5-aza-dC, and then trypsinized and
collected at 24, 48, 72, 96, and 120 hours of treatment.
Viable cells determined by trypan blue (Gibco, Carlsbad, CA)
exclusion were counted using a hematocytometer.
In TUNEL assays, 1 day before treatment, tumor cells
either treated or untreated with 5-aza-dC were plated in four-
well chamber slides. The cells were fixed at each time point
of 24, 72, 96, and 120 hours of treatment by 2% paraformal-
dehyde solution (in phosphate-buffered saline [PBS], pH 7.4)
for 60 minutes at room temperature, permeated in 0.1%
Triton X-100/0.1% sodium acetate for 2 minutes on ice,
and then labeled with TUNEL reaction mixture containing
calf thymus DNA terminal transferase and fluorescein-
labeled dNTP at 37jC for 1 hour. After applying antifade
and mounting medium on the slide, fluorescein-labeled cells
were detected by fluorescence microscopy and the ratio of
the number of labeled cells versus the number of total cells
was obtained by counting the cells of 10 observation fields.
In the cell cycle analysis, both 1 mM 5-aza-dC–treated
and untreated cells were collected at 24, 48, 72, 96, and 120
hours of treatment in PBS buffer containing 10 mM glucose
and then fixed in 70% ethanol at 4jC for at least 1 hours. The
cells were then stained for 30 minutes in propidium iodide
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Figure 1. Cell proliferation assay, TUNEL assay, and cell cycle analysis for
NCI-H522 cells treated with 1 M 5-aza-dC. Cell proliferation assay (A) dem-
onstrated that cells started slower growth at the second day of 5-aza-dC
treatment. TUNEL assay (B) showed that about 13% of cells becomes
apoptotic in drug-treated cells compared with 2% of apoptotic cells in un-
treated cells. Cell cycle analysis (C) indicated that 5-aza-dC treatment can
cause a significant S-phase arrest in the cell cycle.
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solution containing 7.5 mM propidium iodide, 10 mM glu-
cose, and 100 U/ml RNase A in PBS buffer. Flow cytometric
analysis was performed using a FACS Calibur flow cytom-
eter (Becton Dickinson Immunocytometry Systems, San
Jose, CA), which was equipped with Cell Quest version
3.1f software (Becton Dickinson Biosciences, San Jose,
CA) for cell cycle data collection. Cell cycle distribution was
analyzed using ModFit LT Version 2.0 software (Verity
Software House, Inc., Topsham, ME).
cDNA Expression Array Analysis and Reverse Transcrip-
tion–Polymerase Chain Reaction (RT-PCR) Confirmation
for Gene Expression
Polyadenylated RNA from 5-aza-dC–treated NCI-H522
and untreated control cells was extracted with TriZol reagent
(Life Technologies, Inc., Grand Island, NY) and purified with
magnetic oligo(dT) beads (DYNAL, Inc., Lake Success, NY).
In each cDNA array analysis, 0.6 mg of mRNA was radio-
labeled with a mixture of gene-specific primers during the
reverse transcription procedure. The labeled probe of a total
of 7.5  106 cpm activity was hybridized with each array
membrane. Membrane washing was performed by following
the procedure described in the user’s manual. The hybrid-
ized membrane was exposed to a PhosphoImage plate and
processed using Software ImageQuant Version 3.3 (Molec-
ular Dynamics, Sunnyval, CA). The quantitative data anal-
ysis was performed using AtlasImage 2.0 Software (cat no.
V1212-1; Clontech). For verifying the alterations of gene
expression detected by cDNA array analysis, total full-length
cDNA of both treated and untreated cells were synthesized
by reverse transcription and amplified by the SMART PCR
cDNA Synthesis Kit in a low cycle number (BD Biosciences,
Palo Alto, CA). All cDNA samples were diluted into equal
concentration according to the PCR production of GAPDH
before use in the comparison of gene expression.
Antisense Oligo Transfection and Full-Length cDNA
Transfection
For antisense oligo transfection, a stretch of 23-bp-long
DNA sequences of tyrosine protein kinase ABL2 (ABL2 )
cDNA from Genebank (accession no. M35296) was chosen
for synthesizing both sense and antisense oligos (sense,
agagcagggatggggcagcaggt; antisense, acctgctgccccatccct-
gctct), which cover the ATG start codon of the gene. Both
oligos are incorporated with phosphorothioate to increase
their intracellular stability. In each transfection, 0.55 mM oligo
and 10 mg of lipofectamine in 1 ml of serum-free 1640
medium were applied to the growing cells in a T-25 flask
containing 0.5  106 to 1  106 cells. Triplicate flasks for
both sense and antisense oligo transfection were used.
After incubation at 37jC for 8 hours, 4 ml of complete RPMI
1640 medium was added and cells were incubated for
another 48 hours, and then trypsinized and counted. In cDNA
transfection studies, the full-length cDNA of the Hint/PKCI-1
or TRP-1 gene, amplified by RT-PCR from cell line NCI-
H522, were cloned into the XhoI recognition site of the
pLXSN vector (Clontech). Primer sequences used for clon-
ing the full-length cDNA of the Hint/PKCI-1 gene were:
upstream, acgtctcgaggcgagatggcagatgagattg; downstream,
atgtctcgagacgtgcttaaccaggaggccaatg. Primer sequences for
cloning full-length cDNA of TRP-1 gene were: upstream,
gaccctcgagcagaatgagtgctcctaaactcc; downstream, gctactc-
gagagtagggcatttgttagaccacagac. The insert and its orienta-
tion from recombinant clones were confirmed by restriction
analysis and DNA sequencing. Five micrograms of plasmid
DNA containing either forward-oriented or reverse-oriented
Figure 2. A representative cDNA array analysis of NCI-H522 cells. The
changes in gene expression, either downregulation or upregulation, after
4 days of 1 M 5-aza-dC treatment are indicated by arrows.
Figure 3. RT-PCR confirmation of the alterations in gene expression identified by cDNA array analysis in NCI-H522 cell line. ERK6, ABL2, Myt1, RGC1, RAD21H,
KRS2, hEGR1, ITGB8, and ARAF1 genes are downregulated, whereas CKS1, CKS2, S100-A4, TXBP151, CAF1, HP1, and TIMP-1 genes are upregulated by 1 M
5-aza-dC treatment for 4 days.
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full-length cDNA in the expression vector was used in each
lipotransfection. After 48 hours of incubation, cells were
selected by 200 mg/ml G418 for about 20 days. The mixture
of G418-resistant clones was then collected.
Nude Mice Tumorigenicity Assay
Exponentially growing cells collected from stable trans-
fection were harvested and resuspended in serum-free
medium. After washing twice with serum-free medium,
2  106 cells were inoculated subcutaneously at the proxi-
mal dorsal midline of 4- to 6-week–old female Balb/c athymic
nude mice (Jackson Laboratories, Inc., Bar Harbor, ME).
Tumor size was measured in two dimensions twice a week.
Tumor tissue generated at the injection site was dissected at
the end of the assay, fixed in 4% paraformaldehyde buffer
(pH 7.0), and embedded in paraffin for pathologic examina-
tion. The weight of tumor dissected was measured and a
t-test was used to compare the numbers obtained from
different injection groups. Tumor growth was typically ob-
served for 90 days. Following the institute’s guidance on
animal care, nude mice with steadily growing tumors reach-
ing a size of 10–15  10–15 mm2 were sacrificed before the
end of observation period. Histopathologic examination was
performed on the specimens stained with hematoxylin and
eosin.
Results
5-Aza-dC Induces Cell Apoptosis and Cell Cycle Arrest in
NCI-H522 Cells
To find an appropriate cell line whose response to 5-aza-
dC is derived mainly from drug-induced DNA demethylation,
five NSCLC cell lines were screened by 1 mM 5-aza-dC
treatment for 4 days. In all lines, 5-aza-dC caused a signif-
icant inhibition of cell growth compared to the untreated cell
lines. However, all but the NCI-H522 cell line exhibited
profound cytotoxicity as demonstrated by dramatic cell death
Table 1. Alterations in Gene Expression in NCI-H522 Cells Treated by 5-Aza-dC.
Accession Gene or Protein Name (Symbol) Primers User for RT-PCR
Genes downregulated by 5-aza-dC
L07868 ERBB4 receptor tyrosine kinase cttcaagcattggataatoccgaatatcac/agcttacaccacagtattocggtgtctgta
L24038 A-raf protooncogene homolog 1 (ARAF1) tcaaagtatacctgcocaacaagcaac/cttcaaggaoctcgacaatgagctc
AF010310 p53-induced protein gtgcgcagatcggctatgaggacc/gggtgoccttcatgaggctgctg
X79483 Extracellular signal – regulated kinase 6 (ERK6) agctgaagatcctggacttcggoc/gggaggcccttcatgtagttcttgg
M35296 Tyrosine protein kinase ABL2 (ABL2) aggtagctgaggagcttgggagag/tttgctttcgaggcagtgctgggg
AF014118 Membrane-associated kinase 1 (MYT1) gggocatggctcctacggagag/ccaggcttcacagtgttgctgcag
D87119 Cancellous bone osteoblast ccagctggtgccggacgtcaac/ccatgctacgtggtcagtcagctc
U48296 pTPCAAX1 nuclear tyrosine phosphatase cctggttgttgtattgctgttcattgc/tgaccgttggaatctttgaaacgcag
X78817 rho-GAP hematopoietic protein C 1 (RGC1) ctgcttagcctggctagtgtcaacg/gtctcaatggtctgtcggtocagg
U60207 Serine/threonine protein kinase KRS2 (KRS2) ggcttgcctcatgtttgttagccag/ctcaactaggagtctctgttcctgg
D38551 RAD21 (S. pombe) homolog (RAD21H) gtatcaatgggtgggcctgatagtc/gggctctaattgtcttgctatccaac
U43431 DNA topoisomerase III a gagaccacagtggagatcgacatcg/gcatocgtaccaatgccatgcttct
X52541 Early growth response protein 1 (hEGR1) tggcttccaggttoccatgatoccc/ggcaagcgtaagggcgttcgtggg
M73780 Integrin precursor (ITGB8) gtgcccaatgacggaaactgtcatctg/cattgctcgtcactttctgcatocttc
Genes upregulated by 5-aza-dC in NCI-H522 cells
M63618 Bullous pemphigoid antigen 1 tgttgcagggtattggctgactgctag/gagtgaacctgtggctctatcaacoct
M73980 Notch protein homolog 1 cgcaggcttcagcgggatocac/gtactgggtgtgggtctgccagc
M14505 Cyclin-dependent kinase 4 (CDK4) cttcocatcagcacagttcgtgagg/cttgactgttccaocacttgtcacc
X54941 Cyclin-dependent kinase regulatory subunit 1 (CKS1) catgtcgcacaaacaaatttactattcgg/agatgtgaggttctggttcatggatc
X54942 Cyclin-dependent kinase regulatory subunit 2 (CKS2) agtctocggcgagttgttgcctg/gactctgttggacaccaagtctcc
U51004 Hint protein; protein kinase C inhibitor 1 (Hint/PKCI-1) gaagatcatocgcaaggaaataccag/cttattcaggcccagatcagcagc
M80563 S100 calcium-binding protein A4(S100-A4) gtttgatcctgactgctgtcatgg/gcatcaagcacgtgtctgaaggagc
U46461 Dishevelled 1 (DVL1) tcaccatcgccaatgccgtcatcg/tggagccactgttgaggttcaggg
U33821 TAXI-binding protein 1 51 (TXBP151) tcctgatcctccaagtcaacatttacg/caaacacctgctggtcatagtcagg
U56390 Caspase-9 (CASP9) agctggacgccatatctagtttgccc/ggtgcaagataaggcagggtgaggg
M15796 Proliferating cyclic nuclear antigen (PCNA) gaaggtgttggaggcactcaaggac/ggtgcttcaaatactagcgccaagg
L07515 Heterochromatin protein homolog 1 (HP1) gggcagacgttagcgtgagtgatc/atattccacttgtoccttaaocacgc
X74262 Chromatin assembly factor 1 p48 subunit (CAF1) agagtgcaaoccagacttgcgtctoc/ocaggaaacatcttctactactgccg
X03124 Tissue metalloproteinase inhibitor 1 (TIMP1) tgcaattccgacctcgtcatcagggc/agaaactcctcgctgcggttgtggg
U36223 Fibroblast growth factor 8 ccaacaagcgcatcaacgccatgg/cagccctcgtacttggcattctgc
X51420 Tyrosinase-related protein 1 (TRP-1) ctgcacggatgacttgatgggatcc/cttocaagcactgagcgacatcctg
Table 2. Suppression of In Vivo Tumorigenicity by Hint/PKCI-1 in NCI-H358 Cell Line.
Cell Lines/Transfection Latency (days) Tumor Weight (g) Number of Tumors/Mice
NCI-H358/vector 1824 0.310 ± 0.080 3/3
NCI-H358/Hint/PKCI-1 1824 0.120 ± 0.025 (P < .01) 3/3
NCI-H358/vector* 1722 0.350 ± 0.080 3/3
NCI-H358/Hint/PKCI-1* 1924 0.130 ± 0.020 (P < .01) 3/3
*Numbers were obtained from the repeated experiments.
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and detachment from culturing flask after 5-aza-dC treat-
ment. 5-Aza-dC–induced cell growth inhibition in NCI-H522
cells was further characterized by cell proliferation assay,
TUNEL assay, and cell cycle analysis. The cell proliferation
assay showed that a slowdown on cell growth started at
48 hours after 1 mM 5-aza-dC treatment, followed by nearly
a complete cessation of cell proliferation (Figure 1A). The
TUNEL assay showed that apoptotic cells started to increase
on the third day after 5-aza-dC treatment and reached 13%
on the fifth day postdemethylation treatment compared with
2% in untreated cells (Figure 1B). The flow cytometry assay
indicated that the percentage of cells in S-phase was dra-
matically increased on the fifth day of 1 mM 5-aza-dC
treatment (Figure 1C). These data indicated that the 5-aza-
dC–induced cell growth inhibition was partially attributable to
cell cycle arrest and apoptosis.
Alterations of mRNA Expression Were Identified in 5-Aza-
dC–Treated NCI-H522 Cells
To avoid ambiguity caused by potential 5-aza-dC–in-
duced cytotoxicity during gene expression analysis, only
the NCI-H522 cell line was chosen for cDNA array analysis.
To identify genes undergoing changes in mRNA expression
after 5-aza-dC treatment, a membrane cDNA array analysis
covering 1176 genes was employed. The cDNA array anal-
ysis was performed by using a comparison between 4 days
of 1 mM 5-aza-dC–treated and untreated cells. Quantitative
cDNA array data were determined by the ratio of the adjusted
intensity of each gene with that of the average of all house-
keeping genes provided in the same cDNA array, including
ubiquitin and GAPDH. Under our experimental conditions,
the average intensity values of all housekeeping genes
were consistent with that of ubiquitine and GAPDH be-
tween treated and untreated cells. The genes with an abso-
lute adjusted intensity over 500 and with a ratio difference
over five-fold between treated and untreated samples were
chosen for further analysis. A representative cDNA array
analysis is shown in Figure 2. Alteration of mRNA expression
of a total of 73 genes was determined by these criteria from
Figure 5. Cell number counting after antisense oligo transfection for ABL2
gene in human NSLCLC cell lines showing downregulation of ABL2 gene
after 5-aza-dC treatment. Significant differences in cell numbers between
sense oligo– transfected (S-ABL2) and antisense oligo– transfected (AS-
ABL2) cells were observed in NCI-H522, NCI-H358, and NCI-H23 cells.
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Figure 4. RT-PCR to detect the expression of candidate genes in five human NSCLC cells lines treated by 1 M 5-aza-dC. Downregulation of the ABL2 and
upregulation of the CAF1, DVL1, Hint/PKCI-1, TIMP-1, and TRP-1 genes were found in three, three, three, two, two, and three of five cell lines, respectively. The
expression of GAPDH was used as quantitative standard.
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repeated experiments. After further confirmation by RT-
PCR, 30 genes, either downregulated or upregulated in
5-aza-dC– treated cells, were considered as candidate
genes for further characterization (Table 1). Examples such
as downregulation of ABL2, membrane-associated protein
(Myt-1), Rho-Gap hematopoietic protein C1 (RGC1), and
early growth response protein 1 (hEGR1) genes; and upre-
gulation of Hint/PKCI-1, dishevelled 1 (DVL1), chromatin
assembly factor 1 (CAF1), tissue metalloproteinase inhibitor
1 (TIMP-1), and tyrosinase-related protein 1 (TRP-1) genes
are shown in Figure 3.
Genes Showing Alteration in mRNA Expression in Multiple
5-Aza-dC–Treated NSCLC Cell Lines
To determine which genes showed recurrent changes in
gene expression in multiple cell lines, the detection of mRNA
expression of all 30 candidate genes was expanded to NCI-
H23, NCI-H358, HCI-H520, and A549 cell lines treated
similarly with 5-aza-dC. All RNA samples used in these
detections were equally quantified relative to the expression
of the GAPDH gene. The downregulation of ABL2 gene and
the upregulation of Hint/PKCI-1, CAF1, DVL1, TIMP-1, and
TRP-1 genes were observed in three, two, three, three, two,
and three of five cell lines treated with 5-aza-dC, respec-
tively (Figure 4).
Upregulation of Hint/PKCI-1 Gene Was Directly Associated
with Demethylation-Induced Cell Growth Inhibition
To determine the association of the alterations in gene
expression of the candidate genes with DNA demethylation–
induced cell growth inhibition, ABL2, Hint/PKCI-1, and TRP-
1 were selected for functional analysis. The antisense oligo
transfection for the ABL2 gene and full-length cDNA trans-
fection for theHint/PKCI-1 and TRP-1 genes were performed
in cell lines that showed alterations in mRNA expression of
these genes after DNA demethylation treatment. A signifi-
cant cell growth inhibition was observed in ABL2 antisense
oligo-transfected NCI-H522, NCI-H23, and NCI-H358 cell
lines compared with each sense oligo-transfected cell line
(Figure 5). No difference in ABL2 mRNA expression was
observed between antisense oligo and sense oligo-trans-
fected cells (data not shown). The attempt to detect the
change in protein level after antisense oligo transfection
failed due to the lack of antibody against ABL2 protein. In
Hint/PKCI-1 full-length cDNA transfection study, a marked
cell growth inhibition in cell proliferation assays using 2%
serum was observed in both NCI-H522 and NCI-H358 cells
lines (Figure 6). However, no obvious cell growth inhibition
was observed in TRP-1 cDNA-transfected A549, NCI-H23,
and NCI-H522 cell lines. The expression of the transfected
gene was detected by RT-PCR only in cells transfected with
forward-oriented cDNA in expression vector (data not
shown).
Hint/PKCI-1 Gene Reduced In Vivo Tumorigenicity of NCI-
H358 Cells
To assess the suppressive effect of the Hint/PKCI-1 gene
on tumorigenic potential of both NCI-H522 and NCI-H358
cells, we tested the tumorigenicity of two stably transfected
cell lines in nude mice. Animals that received NCI-H358
cells transfected with either pLXSN-Hint/PKCI-1(+) or
pLXSN alone developed tumors during the first 4 weeks of
the experiment. However, tumors from pLXSN alone contin-
ued to grow progressively during the observation period,
whereas tumors from Hint/PKCI-1(+) transfection exhibited a
significantly slower growth over the entire period of the
examination. The difference in tumor size between two
injection groups was very significant (P < .01). Histopatho-
logic analysis of the tumors was consistent with lung adeno-
carcinoma. The NCI-H522 cell line, although derived from
lung adenocarcinoma, did not produce tumors in nude mice.
The nude mice in vivo tumorigenicity assays were re-
peated twice and the results are summarized in Table 2.
Discussion
Our experiments show that 5-aza-dC can significantly induce
the inhibition of in vitro growth of human NSCLC cell lines
through DNA demethylation– induced changes in gene ex-
pression. The observations of cell apoptosis and cell cycle
arrest in S-phase in 5-aza-dC–treated NCI-H522 cells, two
contributing factors to drug-induced cell growth inhibition,
are consistent with the general understanding of the
Figure 6. Cell proliferation assays for NCI-H522 and NCI-H358 cell lines transfected with Hint/PKCI-1 cDNA. Slower growth was observed in both cell lines
transfected with forward-oriented cDNA, indicated as Hint/PKCI-1(+), in pLXSN expression vector as compared with that transfected with reverse-oriented cDNA,
labeled as Hint/PKCI-1().
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consequence of 5-aza-dC– induced DNA demethylation.
These changes in tumor cell phenotypes are believed to be
based on the induction of alterations in gene expression.
During the course of growth inhibition of NCI-H522 cells, the
mRNA expression of 16 genes was upregulated, whereas
that of 14 genes was downregulated in over 1000 genes
tested in cDNA array analysis. These genes belong to
different categories in terms of regulation of cell functions.
The CKS1 gene, for example, is involved in the regulation of
cell cycle [26]; theCASP9 gene is implicated in the regulation
of cell apoptosis [27]; and the ERK6 gene may contribute to
cell transformation [28]. However, the genes with recurrent
alteration in other 5-aza-dC–treated cell lines are also more
likely involved in the regulation of cell growth. The expression
of the ABL2, Hint/PKCI-1, DVL1, CAF1, TIMP-1, and TRP-1
genes was found to be altered in more than two NSCLC cell
lines used in this study, implying a contribution of these
genes to cell growth inhibition in multiple NSCLCs.
Our data strongly suggest that the Hint/PKCI-1 gene
functions as a negative regulator of tumor cell growth be-
cause 5-aza-dC–induced upregulation of the Hint/PKCI-1
was found in two of five NSCLC cell lines. Overexpression of
the Hint/PKCI-1 by cDNA transfection resulted in in vitro cell
growth inhibition of these two NSCLC cell lines. In addition,
stable transfection of Hint/PKCI-1 cDNA significantly re-
duced in vivo tumorigenicity of NCI-H358 cells. Hint/PKCI-1
is the only other characterized human histidine triad (HIT)
nucleotide-binding protein in addition to tumor-suppressor
gene FHIT [29], which is a frequent target of genomic
deletion and aberrant DNAmethylation in human lung cancer
as well as other kinds of cancer [30–32]. Like FHIT, the Hint/
PKCI-1 gene is also involved in nucleotide metabolism by
binding nucleotide molecules and hydrolyzing ADP in vitro
[33]. However, the involvement of the Hint/PKCI-1 gene in
carcinogenesis has not been investigated. The Hint/PKCI-1
gene is localized at chromosome 7q21–22, a region of
genomic deletion reported in radon-induced rat lung cancer
[34] and in more invasive human NSCLCs [35]. In addition,
microcell transfer studies suggested the existence of a
metastasis-suppressor gene in this region [36]. Thus, Hint/
PKCI-1 might represent a negative regulator of tumor cell
properties in this region. The examination of Hint/PKCI-1
expression in primary tumors would provide more convincing
evidence on the role of this gene in NSCLCs. In addition, it
would be interesting to see whether gene expression of both
Hint/PKCI-1 and FHIT is altered in NSCLCs.
Downregulation of ABL2 was detected in three of five
NSCLC cell lines treated with 5-aza-dC. In addition, anti-
sense oligo transfection against ABL2 caused a significant
in vitro cell growth inhibition in these three cell lines. How-
ever, in the absence of evidence showing that antisense
strategy resulted in the decrease of protein expression of
ABL2, one cannot speculate that this protooncogene is
involved in the pathogenesis of NSCLC.
Functional exploration of the ABL2, Hint/PKCI-1, and
TRP-1 genes in this study is part of identifying genes in
DNA demethylation–treated NSCLC cells that may be rele-
vant in the pathogenesis of lung cancer. The other candidate
gene selected for future functional characterizations is
CAF1, which was first found to be a retinoblastoma protein
(Rb)–binding protein and a negative regulator of Ras in
yeast [37]. It was later found to be a component of the
histone deacetylase complex recruited by Rb and to mediate
transcriptional repression of E2F1 [38].
In summary, our observations demonstrate that 5-aza-dC
can significantly induce the growth inhibition of human lung
cancer cells by DNA demethylation and the consequent
changes in mRNA expression of multiple genes. Also, our
approach of characterizing the variation of gene expression
during the transition of DNA methylation thus is apparently
efficient in identifying new cancer-related genes. Promoter
methylation status will be characterized to determine wheth-
er the changes in gene expression of these genes are
caused by their own aberrant promoter methylation, or are
derived from the regulation of other genes, which are pri-
marily regulated by DNA demethylation. These studies
should shed more insight into the functional understanding
of the candidate genes identified in this study.
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